Yüklüyor......
Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
Background: The combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is a very effective chemotherapeutic regimen for unresectable pancreatic cancer. Previous studies have reported that female gender may be a predictor of a better response to FOLFIRINOX. This study was...
Kaydedildi:
| Yayımlandı: | J Pers Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7911695/ https://ncbi.nlm.nih.gov/pubmed/33573202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11020083 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|